All In Biotech

Drug Trial Radar · NCT05893537

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

100

Actual

Start

Jun 16, 2023

Primary completion

Mar 4, 2025

Study completion Mar 28, 2025

Sponsor

Lead sponsor
Cognition TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.

Conditions

  • Age-Related Macular Degeneration

Interventions

  • Active Comparator CT1812Drug

    123 participants will receive a single daily dose of CT1812 (200 mg)

  • Placebo ComparatorDrug

    123 participants will receive a single daily dose of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Geographic Atrophy (GA) lesion area over 104 weeks in the study eye.Time frame: Baseline through Week 104

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Phoenix Retina Associates

    Phoenix, Arizona

  • Retinal Consultants Medical Group

    Sacramento, California

  • Bay Area Retina Associates

    Walnut Creek, California

  • Advanced Research

    Deerfield Beach, Florida

  • Rand Eye Institute

    Deerfield Beach, Florida

  • National Ophthalmic Research Institute

    Fort Myers, Florida

  • Center for Retina and Macular Disease

    Winter Haven, Florida

  • Retina Specialists

    Baltimore, Maryland

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • NJ Retina

    Edison, New Jersey

  • Long Island Vitreoretinal Consultants

    Great Neck, New York

  • North Carolina Retina Associates

    Wake Forest, North Carolina

  • Verum Research LLC

    Eugene, Oregon

  • Erie Retina Research, LLC

    Erie, Pennsylvania

  • Tennessee Retina, PC

    Nashville, Tennessee

  • Austin Clinical Research, LLC

    Austin, Texas

  • Star Vision Consultants

    Burleson, Texas

  • Texas Retina Associates

    Fort Worth, Texas

  • Retina Consultants of Texas

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.